Bank of America
SNDX icon

Bank of America’s Syndax Pharmaceuticals SNDX Stock Holding History

Bank of America’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99.3M Sell
4,249,836
-460,910
-10% -$10M 0.01% 1119
2025
Q4 		$99M Buy
4,710,746
+1,012,993
+27% +$17.7M 0.01% 1116
2025
Q3 		$56.9M Sell
3,697,753
-141,119
-4% -$1.85M ﹤0.01% 1634
2025
Q2 		$36M Buy
3,838,872
+967,873
+34% +$10.7M ﹤0.01% 1989
2025
Q1 		$35.3M Buy
2,870,999
+2,625,491
+1,069% +$37M ﹤0.01% 1905
2024
Q4 		$3.25M Sell
245,508
-511,799
-68% -$8.76M ﹤0.01% 4017
2024
Q3 		$14.6M Sell
757,307
-94,899
-11% -$1.96M ﹤0.01% 2699
2024
Q2 		$17.5M Sell
852,206
-802,846
-49% -$16.8M ﹤0.01% 2381
2024
Q1 		$39.4M Buy
1,655,052
+670,794
+68% +$15M ﹤0.01% 1664
2023
Q4 		$21.3M Buy
984,258
+724,400
+279% +$11.1M ﹤0.01% 2102
2023
Q3 		$3.77M Sell
259,858
-24,009
-8% -$454K ﹤0.01% 3664
2023
Q2 		$5.94M Sell
283,867
-111,302
-28% -$2.32M ﹤0.01% 3228
2023
Q1 		$8.35M Buy
395,169
+127,457
+48% +$3.17M ﹤0.01% 3011
2022
Q4 		$6.81M Sell
267,712
-34,416
-11% -$803K ﹤0.01% 3089
2022
Q3 		$7.26M Buy
302,128
+226,494
+299% +$5.08M ﹤0.01% 2958
2022
Q2 		$1.46M Sell
75,634
-38,021
-33% -$633K ﹤0.01% 4577
2022
Q1 		$1.98M Sell
113,655
-75,282
-40% -$1.27M ﹤0.01% 4602
2021
Q4 		$4.13M Buy
188,937
+98,760
+110% +$1.82M ﹤0.01% 3841
2021
Q3 		$1.72M Buy
90,177
+57,340
+175% +$956K ﹤0.01% 4583
2021
Q2 		$564K Sell
32,837
-70,274
-68% -$1.29M ﹤0.01% 5320
2021
Q1 		$2.31M Buy
103,111
+56,484
+121% +$1.28M ﹤0.01% 4136
2020
Q4 		$1.04M Buy
46,627
+21,001
+82% +$436K ﹤0.01% 4470
2020
Q3 		$378K Sell
25,626
-20,196
-44% -$308K ﹤0.01% 4924
2020
Q2 		$679K Buy
45,822
+18,923
+70% +$288K ﹤0.01% 4397
2020
Q1 		$295K Sell
26,899
-5,723
-18% -$53.7K ﹤0.01% 4861
2019
Q4 		$287K Buy
32,622
+967
+3% +$7.1K ﹤0.01% 5397
2019
Q3 		$236K Sell
31,655
-8,256
-21% -$75.2K ﹤0.01% 5562
2019
Q2 		$371K Sell
39,911
-71,138
-64% -$519K ﹤0.01% 5266
2019
Q1 		$582K Sell
111,049
-118,042
-52% -$673K ﹤0.01% 4907
2018
Q4 		$1.02M Buy
229,091
+170,305
+290% +$934K ﹤0.01% 4392
2018
Q3 		$475K Buy
58,786
+30,702
+109% +$219K ﹤0.01% 4987
2018
Q2 		$197K Buy
28,084
+26,189
+1,382% +$257K ﹤0.01% 5419
2018
Q1 		$27K Sell
1,895
-3,167
-63% -$33.6K ﹤0.01% 6282
2017
Q4 		$44K Buy
5,062
+4,556
+900% +$45.1K ﹤0.01% 6113
2017
Q3 		$6K Buy
506
+203
+67% +$2.49K ﹤0.01% 6682
2017
Q2 		$4K Sell
303
-531
-64% -$6.07K ﹤0.01% 6643
2017
Q1 		$11K Buy
834
+187
+29% +$1.94K ﹤0.01% 6520
2016
Q4 		$5K Sell
647
-201
-24% -$2.2K ﹤0.01% 6707
2016
Q3 		$14K Buy
848
+759
+853% +$9.98K ﹤0.01% 6266
2016
Q2 		$1K Buy
+89
New +$1.22K ﹤0.01% 7008

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's SNDX Position: Q1 2026 in Review

Bank of America reduced its Syndax Pharmaceuticals (SNDX) stake by 9.8% in Q1 2026, selling an estimated $10M and leaving 4,249,836 shares worth $99.3M. The position accounts for 0.01% of the portfolio, ranked #1119.

Bank of America first reported a position in SNDX in Q2 2016 and has held it in 40 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Bank of America held 4,249,836 shares of Syndax Pharmaceuticals worth $99.3M as of Q1 2026.
  • Bank of America sold 460,910 Syndax Pharmaceuticals shares in Q1 2026, an estimated $10M.
  • Syndax Pharmaceuticals made up 0.01% of Bank of America's portfolio in Q1 2026, its #1119 holding.
  • Bank of America first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 40 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.